Induced sensitivity to EGFR inhibitors is mediated by palmitoylated cysteine 1025 of EGFR and requires oncogenic Kras
Authors:
- 1 November 2017
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 493 (1) , 213-219
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (R01CA181633)
- ACS (RSG-15-027-01)
- Pennsylvania Department of Health
This publication has 18 references indexed in Scilit:
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- Protein palmitoylation and subcellular traffickingBiochimica et Biophysica Acta (BBA) - Biomembranes, 2011
- DHHC palmitoyl transferases: substrate interactions and (patho)physiologyTrends in Biochemical Sciences, 2011
- Palmitoylation and depalmitoylation dynamics at a glanceJournal of Cell Science, 2010
- Protein palmitoylation in neuronal development and synaptic plasticityNature Reviews Neuroscience, 2010
- 2-Bromopalmitate and 2-(2-hydroxy-5-nitro-benzylidene)-benzo[b]thiophen-3-one inhibit DHHC-mediated palmitoylation in vitroJournal of Lipid Research, 2009
- Palmitoylation Controls Recycling in Lysosomal Sorting and TraffickingTraffic, 2008
- Palmitoylation: policing protein stability and trafficNature Reviews Molecular Cell Biology, 2007
- Epidermal growth factor receptor (EGFR) signaling in cancerGene, 2006
- Epidermal growth factor receptor: mechanisms of activation and signallingExperimental Cell Research, 2003